ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Toulouse White Biotech (TWB) is a good example to how scaling and collaboration through production partnerships can help the industrial biotech sector to satisfy the urgent need to speed up and scale sustainable processes for industrial production.
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Both the US Skokie and European Rankweil sites address customer needs in early-phase drug development
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BVs propietary ADC platform.
A new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
Researchers have presented a novel method to promote biofilm formation. They believe their method can help to increase the efficiency of biocatalysis in biotechnological production processes and thus allow cost-effective recycling of waste, as well as carbon dioxide conversion into chemical building blocks and natural gas,
or amino acids.
Last year, the G7 heads declared to end funding for the oil industry by the end of this year. At the COP27 in November, the WHO and United Nations renewed promises to redirect the hundreds of billions of dollars invested annually in fossil fuels to fund renewable energy initiatives.
British researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Asher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.
Strategic planning for the development of a novel therapy is critically important to reduce financial burdens, save time, and find the best, shortest path forwards. No two products will have the same pathway or same criterion for optimisation, but early, forward-looking planning can result in greater efficiency and a better understanding of key decisions and timepoints along the course of novel therapy development.